Evaluation of Tolerability and Safety of "Allergovac Poliplus" in Polysensitized Patients With Rhinitis or Allergic Rhinoconjunctivitis With or Without Asthma: A Study in Daily Clinical Practice

Launched by ROXALL MEDICINA ESPAÑA S.A · Jul 25, 2016

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients aged between 5 and 60 years who present rhinitis or allergic rhinoconjunctivitis caused by IgE-mediated sensitization to more than one allergen source with or without mild / moderate asthma.
• • 2. Patients eligible for immunotherapy treatment with Allergovac Poliplus according to investigator criteria.
• • 3. Patients must provide written informed consent. It is the case of children , the legal representative or tutor of the child must sign the inform consent form.
• Exclusion Criteria:
• • 1. Patients that according to the investigator criteria may present difficulties for understanding the patient information sheet, completing the questionnaires and self-administered scales.
• • 2. Patients that according to the investigator may present difficulties to complete the patient diary.
• • 3. Patients who are participating in another clinical trial or observational study.